Press coverage about Vitae Pharmaceuticals (NASDAQ:VTAE) has been trending somewhat positive on Monday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vitae Pharmaceuticals earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.1684882950361 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Vitae Pharmaceuticals (NASDAQ VTAE) remained flat at $21.00 during midday trading on Monday. Vitae Pharmaceuticals has a 12-month low of $4.08 and a 12-month high of $21.03. The company has a 50 day moving average price of $18.81 and a 200 day moving average price of $11.50.

COPYRIGHT VIOLATION NOTICE: “Vitae Pharmaceuticals (VTAE) Getting Somewhat Positive Media Coverage, Study Finds” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at

About Vitae Pharmaceuticals

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Insider Buying and Selling by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)

Receive News & Stock Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.